These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 22523364)

  • 1. Matrix metalloproteinases and their inhibitors in pulmonary hypertension.
    Chelladurai P; Seeger W; Pullamsetti SS
    Eur Respir J; 2012 Sep; 40(3):766-82. PubMed ID: 22523364
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Smooth muscle cell matrix metalloproteinases in idiopathic pulmonary arterial hypertension.
    Lepetit H; Eddahibi S; Fadel E; Frisdal E; Munaut C; Noel A; Humbert M; Adnot S; D'Ortho MP; Lafuma C
    Eur Respir J; 2005 May; 25(5):834-42. PubMed ID: 15863640
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of matrix metalloproteinases by lung TIMP-1 gene transfer limits monocrotaline-induced pulmonary vascular remodeling in rats.
    Vieillard-Baron A; Frisdal E; Raffestin B; Baker AH; Eddahibi S; Adnot S; D'Ortho MP
    Hum Gene Ther; 2003 Jun; 14(9):861-9. PubMed ID: 12828857
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Matrix metalloproteinases (MMPs) and tissue inhibitors of MMPs in the respiratory tract: potential implications in asthma and other lung diseases.
    Gueders MM; Foidart JM; Noel A; Cataldo DD
    Eur J Pharmacol; 2006 Mar; 533(1-3):133-44. PubMed ID: 16487964
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relevance of tenascin-C and matrix metalloproteinases in vascular abnormalities in murine hypoplastic lungs.
    Chinoy MR; Miller SA
    Biol Neonate; 2006; 90(3):185-96. PubMed ID: 16699260
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiremodeling effects of iloprost and the dual-selective phosphodiesterase 3/4 inhibitor tolafentrine in chronic experimental pulmonary hypertension.
    Schermuly RT; Kreisselmeier KP; Ghofrani HA; Samidurai A; Pullamsetti S; Weissmann N; Schudt C; Ermert L; Seeger W; Grimminger F
    Circ Res; 2004 Apr; 94(8):1101-8. PubMed ID: 15031263
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of microRNA-17 improves lung and heart function in experimental pulmonary hypertension.
    Pullamsetti SS; Doebele C; Fischer A; Savai R; Kojonazarov B; Dahal BK; Ghofrani HA; Weissmann N; Grimminger F; Bonauer A; Seeger W; Zeiher AM; Dimmeler S; Schermuly RT
    Am J Respir Crit Care Med; 2012 Feb; 185(4):409-19. PubMed ID: 22161164
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Series "matrix metalloproteinases in lung health and disease": Matrix metalloproteinases in COPD.
    Churg A; Zhou S; Wright JL
    Eur Respir J; 2012 Jan; 39(1):197-209. PubMed ID: 21920892
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Localization of matrix metalloproteinases, (MMPs) their tissue inhibitors, and vascular endothelial growth factor (VEGF) in growth plates of children and adolescents indicates a role for MMPs in human postnatal growth and skeletal maturation.
    Haeusler G; Walter I; Helmreich M; Egerbacher M
    Calcif Tissue Int; 2005 May; 76(5):326-35. PubMed ID: 15868281
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Matrix metalloproteinases and their tissue inhibitors in hypertension-related pregnancy complications.
    Karthikeyan VJ; Lane DA; Beevers DG; Lip GY; Blann AD
    J Hum Hypertens; 2013 Feb; 27(2):72-8. PubMed ID: 22418748
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined effects of the ATP-sensitive potassium channel opener pinacidil and simvastatin on pulmonary vascular remodeling in rats with monocrotaline-induced pulmonary arterial hypertension.
    Jiang L; Zhou T; Liu H
    Pharmazie; 2012 Jun; 67(6):547-52. PubMed ID: 22822545
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Imbalance between matrix metalloproteinases and tissue inhibitor of metalloproteinases in hypertensive vascular remodeling.
    Castro MM; Rizzi E; Prado CM; Rossi MA; Tanus-Santos JE; Gerlach RF
    Matrix Biol; 2010 Apr; 29(3):194-201. PubMed ID: 19969080
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MMP expression and abnormal lung permeability are important determinants of outcome in IPF.
    McKeown S; Richter AG; O'Kane C; McAuley DF; Thickett DR
    Eur Respir J; 2009 Jan; 33(1):77-84. PubMed ID: 18829682
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Matrix metalloproteinases and atherosclerosis. Therapeutic aspects].
    Beaudeux JL; Giral P; Bruckert E; Foglietti MJ; Chapman MJ
    Ann Biol Clin (Paris); 2003; 61(2):147-58. PubMed ID: 12702469
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The distribution of matrix metalloproteinases and tissue inhibitors of metalloproteinases in the lungs of congenital diaphragmatic hernia patients and age-matched controls.
    Masumoto K; de Rooij JD; Suita S; Rottier R; Tibboel D; de Krijger RR
    Histopathology; 2006 Apr; 48(5):588-95. PubMed ID: 16623785
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Extracellular matrix remodelling in human aortic valve disease: the role of matrix metalloproteinases and their tissue inhibitors.
    Fondard O; Detaint D; Iung B; Choqueux C; Adle-Biassette H; Jarraya M; Hvass U; Couetil JP; Henin D; Michel JB; Vahanian A; Jacob MP
    Eur Heart J; 2005 Jul; 26(13):1333-41. PubMed ID: 15827062
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lung capillary injury and repair in left heart disease: a new target for therapy?
    Azarbar S; Dupuis J
    Clin Sci (Lond); 2014 Jul; 127(2):65-76. PubMed ID: 24678967
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Suppression of tissue inhibitors of metalloproteinases may reverse severe pulmonary arterial hypertension.
    Tang WL; Guo H; Yang J; Chen B; Wang X
    Cytotherapy; 2011 Apr; 13(4):499-502. PubMed ID: 21105842
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of matrix metalloproteinases and their inhibitors in experimental retinal ischemia-reperfusion injury in rats.
    Zhang X; Sakamoto T; Hata Y; Kubota T; Hisatomi T; Murata T; Ishibashi T; Inomata H
    Exp Eye Res; 2002 May; 74(5):577-84. PubMed ID: 12076079
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases during normal human pulmonary development.
    Masumoto K; de Rooij JD; Suita S; Rottier R; Tibboel D; de Krijger RR
    Histopathology; 2005 Oct; 47(4):410-9. PubMed ID: 16178896
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.